UBS Group
ELDN icon

UBS Group’s Eledon Pharmaceuticals ELDN Stock Holding History

UBS Group’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.69M Sell
547,447
-45,684
-8% -$108K ﹤0.01% 5119
2025
Q4 		$896K Buy
593,131
+499,678
+535% +$1.19M ﹤0.01% 5670
2025
Q3 		$242K Sell
93,453
-32,813
-26% -$95.9K ﹤0.01% 6563
2025
Q2 		$342K Buy
126,266
+103,041
+444% +$309K ﹤0.01% 6335
2025
Q1 		$78.7K Sell
23,225
-295,356
-93% -$1.22M ﹤0.01% 7233
2024
Q4 		$1.31M Buy
318,581
+318,577
+7,964,425% +$1.26M ﹤0.01% 5105
2024
Q3 		$10 Sell
4
-54,997
-100% -$147K ﹤0.01% 9356
2024
Q2 		$145K Buy
55,001
+54,997
+1,374,925% +$131K ﹤0.01% 5894
2024
Q1 		$8 Sell
4
-552
-99% -$985 ﹤0.01% 9118
2023
Q4 		$1K Buy
+556
New +$773 ﹤0.01% 8441
2023
Q3 		– Sell
-32
Closed -$44 – 9577
2023
Q2 		$44 Sell
32
-424
-93% -$884 ﹤0.01% 8616
2023
Q1 		$1.08K Sell
456
-3,536
-89% -$9.47K ﹤0.01% 8820
2022
Q4 		$9.1K Buy
3,992
+2,978
+294% +$7.36K ﹤0.01% 8694
2022
Q3 		$3K Sell
1,014
-3,624
-78% -$11.5K ﹤0.01% 9525
2022
Q2 		$11K Buy
+4,638
New +$14.2K ﹤0.01% 7796
2022
Q1 		– Sell
-3,638
Closed -$16K – 10404
2021
Q4 		$16K Buy
3,638
+3,583
+6,515% +$18.1K ﹤0.01% 8153
2021
Q3 		$0 Hold
55
– – ﹤0.01% 9669
2021
Q2 		$0 Hold
55
– – ﹤0.01% 9470
2021
Q1 		$1K Buy
+55
New +$830 ﹤0.01% 8762
2020
Q4 		– Sell
-233
Closed -$4K – 8480
2020
Q3 		$4K Buy
+233
New +$2.29K ﹤0.01% 7402
2020
Q1 		– Sell
-206
Closed -$2K – 8055
2019
Q4 		$2K Buy
+206
New +$2.18K ﹤0.01% 7825
2019
Q3 		– Sell
-93
Closed -$2K – 8051
2019
Q2 		$2K Buy
+93
New +$4.07K ﹤0.01% 7611
2019
Q1 		– Sell
-59
Closed -$2K – 7810
2018
Q4 		$2K Buy
+59
New +$3.76K ﹤0.01% 7796
2018
Q2 		– Sell
-142
Closed -$13K – 8047
2018
Q1 		$13K Sell
142
-64
-31% -$4.71K ﹤0.01% 6712
2017
Q4 		$15K Buy
206
+14
+7% +$1.06K ﹤0.01% 6754
2017
Q3 		$18K Buy
192
+170
+773% +$14.1K ﹤0.01% 6523
2017
Q2 		$2K Buy
22
+21
+2,100% +$2.14K ﹤0.01% 7368
2017
Q1 		$0 Sell
1
-8
-89% -$1.18K ﹤0.01% 7716
2016
Q4 		$1K Buy
9
+6
+200% +$1.15K ﹤0.01% 7617
2016
Q3 		$1K Hold
3
– – ﹤0.01% 7510
2016
Q2 		$3K Buy
+3
New +$3.31K ﹤0.01% 7321
2016
Q1 		– Sell
-8
Closed -$11K – 7757
2015
Q4 		$11K Buy
8
+2
+33% +$3.48K ﹤0.01% 7219
2015
Q3 		$10K Buy
6
+5
+500% +$10.3K ﹤0.01% 7258
2015
Q2 		$2K Hold
1
– – ﹤0.01% 8189
2015
Q1 		$2K Sell
1
-6
-86% -$13.2K ﹤0.01% 8440
2014
Q4 		$17K Buy
+7
New +$16.6K ﹤0.01% 7870

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group's ELDN Position: Q1 2026 in Review

UBS Group reduced its Eledon Pharmaceuticals (ELDN) stake by 7.7% in Q1 2026, selling an estimated $108K and leaving 547,447 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #5119.

UBS Group first reported a position in ELDN in Q4 2014 and has held it in 36 quarters since. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • UBS Group held 547,447 shares of Eledon Pharmaceuticals worth $1.69M as of Q1 2026.
  • UBS Group sold 45,684 Eledon Pharmaceuticals shares in Q1 2026, an estimated $108K.
  • Eledon Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5119 holding.
  • UBS Group first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 36 quarters since.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.